Decision: Favourable

Study Title:

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Dr Orla Killeen

  • PI Institution:

    Children's Health Ireland at Crumlin

  • Sponsor:

    Sanofi-aventis Recherche & Développement

Scroll to Top